Published in Eur Heart J on March 01, 2001
Origin of symptoms in chronic heart failure. Heart (2005) 1.10
Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure. Int J Exp Pathol (2009) 0.93
Exercise capacity in apparently healthy survivors of cancer. Arch Dis Child (2005) 0.92
Peak oxygen pulse during exercise as a predictor for coronary heart disease and all cause death. Heart (2006) 0.85
What should be the focus in the management of patients with heart failure? The importance of peripheral vision. Eur Heart J (2001) 0.75
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med (2001) 7.05
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet (1997) 6.48
Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J (2000) 4.99
Incidence and aetiology of heart failure; a population-based study. Eur Heart J (1999) 4.56
Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J (2001) 3.49
Wasting as independent risk factor for mortality in chronic heart failure. Lancet (1997) 3.37
The endotoxin-lipoprotein hypothesis. Lancet (2000) 3.03
Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet (1999) 3.01
Survival of patients with a new diagnosis of heart failure: a population based study. Heart (2000) 2.86
Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2000) 2.85
Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur Heart J (1998) 2.73
Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation (1997) 2.69
Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet (2003) 2.64
Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax (2001) 2.50
Knowledge and communication difficulties for patients with chronic heart failure: qualitative study. BMJ (2000) 2.47
Screening for hypertrophic cardiomyopathy. BMJ (1993) 2.31
Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1997) 2.27
Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol (1997) 2.19
Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation (2000) 2.18
Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol (1997) 2.08
Cardiopulmonary exercise testing for prognosis in chronic heart failure: continuous and independent prognostic value from VE/VCO(2)slope and peak VO(2). Eur Heart J (2000) 2.06
Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol (1997) 2.05
Second trimester ambulatory blood pressure in nulliparous pregnancy: a useful screening test for pre-eclampsia? Br J Obstet Gynaecol (1993) 2.04
Severity of heart failure and dosage of angiotensin converting enzyme inhibitors. BMJ (1995) 1.99
Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J (1998) 1.97
Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation (1996) 1.88
The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J (1997) 1.80
Relation of heart rate and blood pressure turbulence following premature ventricular complexes to baroreflex sensitivity in chronic congestive heart failure. Am J Cardiol (2001) 1.79
Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol (1996) 1.76
Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation (2001) 1.75
Quantitative general theory for periodic breathing in chronic heart failure and its clinical implications. Circulation (2000) 1.72
Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol (2001) 1.71
Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol (1999) 1.71
Prognostic value of changes over time in exercise capacity and echocardiographic measurements in patients with chronic heart failure. Eur Heart J (2000) 1.66
Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol (1997) 1.63
Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J (1997) 1.55
Ventricular assist device in severe heart failure: effects on cytokines, complement and body weight. Eur Heart J (2001) 1.53
Circadian pattern of heart rate variability in chronic heart failure patients. Effects of physical training. Eur Heart J (1995) 1.50
Heart Failure 99 -- the MOXCON story. Int J Cardiol (1999) 1.48
The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. Eur Heart J (1999) 1.44
Angiotensin-converting enzyme inhibition and physical training in heart failure. J Intern Med (1991) 1.42
Validation of ambulatory monitors in special populations. Am J Hypertens (1992) 1.40
Non-invasive assessment of vascular function; paradoxical vascular response to intravenous glucose in coronary heart disease. Eur Heart J (2000) 1.39
Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL. Int J Cardiol (2001) 1.38
Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation (1997) 1.38
Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J (2001) 1.35
Risk stratification in chronic heart failure. Eur Heart J (1998) 1.33
Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation (2001) 1.33
Intraventricular conduction delay: a prognostic marker in chronic heart failure. Int J Cardiol (1999) 1.32
Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol (1997) 1.29
Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol (1996) 1.27
Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest (1999) 1.26
Lisinopril and enalapril in hypertension: a comparative study using ambulatory monitoring. J Hum Hypertens (1990) 1.26
Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: clinical implications and role of augmented peripheral chemosensitivity. Circulation (1999) 1.25
Physical training improves skeletal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol (1993) 1.24
A Rapid Access Heart Failure Clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community. Eur J Heart Fail (2000) 1.24
Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet (1998) 1.22
Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J (1999) 1.20
Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol (1998) 1.19
Muscle ergoreceptor overactivity reflects deterioration in clinical status and cardiorespiratory reflex control in chronic heart failure. Circulation (2001) 1.18
Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism? Heart (2005) 1.17
A neural link to explain the "muscle hypothesis" of exercise intolerance in chronic heart failure. Am Heart J (1999) 1.17
Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol (1997) 1.15
Predictors of exercise capacity in chronic heart failure. Eur Heart J (1994) 1.14
Persistent peripheral vasodilation and sympathetic activity in hypotension after maximal exercise. J Appl Physiol (1985) (1993) 1.12
Heart rhythms, ventricular arrhythmias, and death in chronic heart failure. J Card Fail (1996) 1.11
Muscle metaboreceptors in hemodynamic, autonomic, and ventilatory responses to exercise in men. Am J Physiol (1995) 1.11
Clinical characteristics of chronic heart failure patients with an augmented peripheral chemoreflex. Eur Heart J (1997) 1.10
Adaptive servo-ventilation and deadspace: effects on central sleep apnoea. J Sleep Res (2006) 1.10
Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol (2001) 1.09
Explaining fatigue in congestive heart failure. Annu Rev Med (1996) 1.09
Muscle fatigue and dyspnoea in chronic heart failure: two sides of the same coin? Eur Heart J (1995) 1.08
Cachexia and aging: an update based on the Fourth International Cachexia Meeting. J Nutr Health Aging (2009) 1.07
Unreliability of cardiothoracic ratio as a marker of left ventricular impairment: comparison with radionuclide ventriculography and echocardiography. Postgrad Med J (2000) 1.06
Establishment and performance of a magnetic resonance cardiac function clinic. J Cardiovasc Magn Reson (2000) 1.06